ROBERT CHESS - 08 Sep 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
08 Sep 2021
Net transactions value
-$40,419
Form type
4
Filing time
10 Sep 2021, 18:03:02 UTC
Previous filing
26 Aug 2021
Next filing
14 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Options Exercise $110,400 +8,000 +2.9% $13.80 282,273 08 Sep 2021 Direct F1
transaction NKTR Common Stock Sale $128,000 -8,000 -2.8% $16.00 274,273 08 Sep 2021 Direct F1, F2
transaction NKTR Common Stock Options Exercise $141,850 +10,279 +3.7% $13.80 284,552 09 Sep 2021 Direct F1
transaction NKTR Common Stock Sale $164,670 -10,279 -3.6% $16.02 274,273 09 Sep 2021 Direct F1, F3
holding NKTR Common Stock 2,100 08 Sep 2021 by daughter F4
holding NKTR Common Stock 2,100 08 Sep 2021 by son F4
holding NKTR Common Stock 2,100 08 Sep 2021 by daughter F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Common Stock Options Exercise $0 -8,000 -44% $0.000000 10,279 08 Sep 2021 Common Stock 8,000 $13.80 Direct F1
transaction NKTR Common Stock Options Exercise $0 -10,279 -100% $0.000000* 0 09 Sep 2021 Common Stock 10,279 $13.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on September 18, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $15.85 to $16.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F3 This transaction was executed in multiple trades at prices ranging from $15.76 to $16.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F4 The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.